JP2013503823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503823A5 JP2013503823A5 JP2012527196A JP2012527196A JP2013503823A5 JP 2013503823 A5 JP2013503823 A5 JP 2013503823A5 JP 2012527196 A JP2012527196 A JP 2012527196A JP 2012527196 A JP2012527196 A JP 2012527196A JP 2013503823 A5 JP2013503823 A5 JP 2013503823A5
- Authority
- JP
- Japan
- Prior art keywords
- duloxetine
- crystalline duloxetine
- crystalline
- process according
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2009-584A CZ304602B6 (cs) | 2009-09-02 | 2009-09-02 | Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu) |
| CZPV-2009-584 | 2009-09-02 | ||
| PCT/CZ2010/000099 WO2011026449A1 (en) | 2009-09-02 | 2010-09-02 | A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503823A JP2013503823A (ja) | 2013-02-04 |
| JP2013503823A5 true JP2013503823A5 (enExample) | 2013-09-05 |
Family
ID=43413356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527196A Pending JP2013503823A (ja) | 2009-09-02 | 2010-09-02 | （ｓ）‐ｎ‐メチル‐３‐（１‐ナフチルオキシ）‐３‐（２‐チエニル）プロピルアミン塩酸塩（デュロキセチン）の結晶化方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2473497A1 (enExample) |
| JP (1) | JP2013503823A (enExample) |
| KR (1) | KR20120047262A (enExample) |
| CN (1) | CN102482254A (enExample) |
| BR (1) | BR112012004862A2 (enExample) |
| CZ (1) | CZ304602B6 (enExample) |
| EA (1) | EA021528B1 (enExample) |
| IL (1) | IL218329A0 (enExample) |
| MX (1) | MX2012002621A (enExample) |
| WO (1) | WO2011026449A1 (enExample) |
| ZA (1) | ZA201201570B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626735A (zh) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸度洛西汀晶型及其制备方法 |
| CN104478849A (zh) * | 2014-02-14 | 2015-04-01 | 广东东阳光药业有限公司 | 制备去甲肾上腺素再摄取双重抑制剂的方法 |
| CN106265528A (zh) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | 制备药物凝集体的方法 |
| JP2016222628A (ja) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | デュロキセチン塩酸塩の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
| US5362886A (en) | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| DE10212301A1 (de) | 2002-03-20 | 2003-10-02 | Bayer Ag | Verfahren zur Herstellung von Aryl-aminopropanolen |
| PT1539673E (pt) | 2002-07-09 | 2007-11-14 | Lonza Ag | Processo para preparação de beta-aminoálcoois nmonossubstituídos |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| CZ297560B6 (cs) | 2004-10-26 | 2007-02-07 | Zentiva, A. S. | Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu) |
| TW200639161A (en) * | 2005-03-14 | 2006-11-16 | Teva Pharma | Process for the purification of duloxetine hydrochloride |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| GB0612508D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| GB0612509D0 (en) * | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| CZ300116B6 (cs) * | 2006-12-05 | 2009-02-11 | Zentiva, A. S. | Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu |
| WO2008107911A2 (en) * | 2007-03-05 | 2008-09-12 | Lupin Limited | Novel process for preparation of duloxetine hydrochloride |
-
2009
- 2009-09-02 CZ CZ2009-584A patent/CZ304602B6/cs not_active IP Right Cessation
-
2010
- 2010-09-02 CN CN2010800392370A patent/CN102482254A/zh active Pending
- 2010-09-02 MX MX2012002621A patent/MX2012002621A/es not_active Application Discontinuation
- 2010-09-02 EA EA201290127A patent/EA021528B1/ru not_active IP Right Cessation
- 2010-09-02 WO PCT/CZ2010/000099 patent/WO2011026449A1/en not_active Ceased
- 2010-09-02 KR KR1020127004225A patent/KR20120047262A/ko not_active Withdrawn
- 2010-09-02 BR BR112012004862A patent/BR112012004862A2/pt not_active IP Right Cessation
- 2010-09-02 EP EP10771629A patent/EP2473497A1/en not_active Withdrawn
- 2010-09-02 JP JP2012527196A patent/JP2013503823A/ja active Pending
-
2012
- 2012-02-27 IL IL218329A patent/IL218329A0/en unknown
- 2012-03-01 ZA ZA2012/01570A patent/ZA201201570B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| JP2013516473A5 (enExample) | ||
| CN105263917B (zh) | 新abexinostate盐、相关的晶体形式、其制备方法以及含有其的药物组合物 | |
| JP2013503823A5 (enExample) | ||
| RU2021125455A (ru) | Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения | |
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| JP2009520766A5 (enExample) | ||
| JP2017524742A5 (enExample) | ||
| JP2006151999A5 (enExample) | ||
| JP7326295B2 (ja) | オキサゾール化合物結晶 | |
| ES2746939T3 (es) | Procedimiento para la preparación de cristales de clorhidrato de fingolimod | |
| WO2010081341A1 (zh) | N-正丙基-3-(4-甲基苯基)-4-(4-甲磺酰基苯基)-2,5-二氢吡咯-2-酮的i型结晶及其制造方法 | |
| KR20120047262A (ko) | (ｓ)-ｎ-메틸-3-(1-나프틸옥시)-3-(2-티에닐)프로필아민 하이드로클로라이드(듀록세틴)의 결정화 방법 | |
| RU2016148181A (ru) | Способ получения оптически активных энантиомеров пирлиндола и его солей | |
| RU2017136104A (ru) | Кристаллическая соль нинтеданиба диэтансульфоната и способ ее получения и применения | |
| WO2005019199A1 (en) | Amorphous duloxetine hydrochloride | |
| RU2020111829A (ru) | Кристаллическая форма алкинилпиридинового ингибитора пролилгидроксилазы и способ её получения | |
| ES2443523T3 (es) | Procedimiento para la preparación de hidrocloruro de lercanidipina amorfo | |
| RU2019125378A (ru) | Кристаллические формы каботегравира натрия | |
| WO2014195593A2 (fr) | Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant | |
| RU2015125304A (ru) | Способ получения новых кристаллических форм-4(циклопропилметокси)-n-(3, 5-дихлор-1-оксидопиридин-4-ил)-5-метоксипиридин-2-карбоксамида и его кристаллические формы | |
| JP2016222628A (ja) | デュロキセチン塩酸塩の製造方法 | |
| JPH06500097A (ja) | ５−（２−クロロ−１−ヒドロキシエチル）−４−メチルチアゾール含有の医薬製剤 | |
| JP2016172704A (ja) | デュロキセチン塩酸塩の製造方法、及び新規な結晶構造のデュロキセチン塩酸塩 | |
| JP6382660B2 (ja) | オルメサルタンメドキソミルの製造方法 |